United States

Greenphire ClinCard System, Duke collaborate

Thursday, August 27, 2015

Greenphire, a King of Prussia, Pa.-based provider of payment technology for the clinical trials industry, has announced that Duke University has selected its ClinCard system to support financial data management and tracking in more than 3,000 clinical studies that the organization conducts each year. As one of the largest biomedical research enterprises in the U.S., Duke will implement Greenphire’s solution to automate the management of payments, and associated data, it makes to research participants annually.

[Read More]

Agilent, Weill Cornell collaborate on ALS

Thursday, August 27, 2015

Agilent Technologies is collaborating with Dr. Steven Gross, a faculty member in the department of pharmacology at Weill Cornell Medical College in New York, to advance research in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Agilent will provide the latest mass spectrometry technology to support his research, working toward an understanding of how the most common form of the disease develops in the body.

[Read More]

FDA expands use of Promacta

Wednesday, August 26, 2015

The FDA has approved an expanded use for Novartis’ Promacta (eltrombopag) to include children age 1 and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets. Promacta was approved by the FDA as a tablet formulation in June 2015 for children 6 and older and in 2008 for use in adult patients with the same condition.

[Read More]

Ocata receives lupus nephritis grant

Wednesday, August 26, 2015

Ocata Therapeutics, a Marlborough, Mass.-based clinical stage biotechnology company, has been awarded a Small Business Innovation Research (SBIR) phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to fund further preclinical development of Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMC) product for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).

[Read More]

Biocept CFO resigns; interim replacement named

Monday, August 24, 2015

Biocept, a San Diego-based molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, has announced the voluntary resignation of Bill Kachioff, senior vice president and chief financial officer, to pursue other business opportunities. The company also announced that Mark G. Foletta has been appointed as the company’s interim chief financial officer, effective immediately.

[Read More]

Personalized medicine development tied to showing value of companion diagnostics

Monday, August 24, 2015

With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development (CSDD).

[Read More]

DrugDev hiring in Massachusetts

Monday, August 24, 2015

DrugDev, a health technology company, is putting out a call to SaaS developers in the Boston area to join the team behind a cloud-based software platform that enables clinical trial sponsors, CROs and sites to do more clinical trials together.

[Read More]